Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Citi
Merck
Julphar
Fish and Richardson
Cantor Fitzgerald
Boehringer Ingelheim
US Army
Deloitte
McKinsey

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,712,298

« Back to Dashboard

Which drugs does patent 5,712,298 protect, and when does it expire?

Patent 5,712,298 protects DALIRESP and is included in one NDA.

This patent has thirty-five patent family members in twenty-five countries.
Summary for Patent: 5,712,298
Title: Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
Abstract:Compounds of formula (I), in which one of the substituents R1 or R2 stands for hydrogen, 1-6C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, benzyloxy or totally or partially fluorine-substituted 1-4C-alkoxy, and the other stands for totally or partially fluorine-substituted 1-4C-alkoxy, and R3 stands for phenyl, pyridyl, R31, R32 and R33-substituted phenyl or R34, R35, R36 and R37-substituted pyridyl, in which R31 stands for hydroxy, halogen, cyano, carboxyl, trifluoromethyl 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, 1-4C-alkylcarbonyloxy, amino, mono- or di-1-4C-alkylamino or 1-4C-alkylcarbonylamino; R32 stands for hydrogen, hydroxy, halogen, amino, trifluoromethyl, 1-4C-alkyl or 1-4C-alkoxy; R33 stands for hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy; R34 stands for hydroxy, halogen, cyano, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl or amino; R35 stands for hydrogen, halogen, amino or 1-4C-alkyl; R36 stands for hydrogen or halogen; and R37 stands for hydrogen or halogen. These compounds constitute new effective bronchotherapeutic drugs. ##STR1##
Inventor(s): Amschler; Hermann (Radolfzell, DE)
Assignee: BYK Gulden Lomberg Chemische Fabrik GmbH (Konstanz, DE)
Application Number:08/564,322
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 5,712,298

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms DALIRESP roflumilast TABLET;ORAL 022522-001 Feb 28, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,712,298

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland01 996/99Jul 02, 1993
PCT Information
PCT FiledJuly 02, 1994PCT Application Number:PCT/EP94/02169
PCT Publication Date:January 12, 1995PCT Publication Number: WO95/01338

International Patents Family Members for US Patent 5,712,298

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 217612 ➤ Subscribe
Australia 687087 ➤ Subscribe
Australia 7490794 ➤ Subscribe
Canada 2165192 ➤ Subscribe
China 1046939 ➤ Subscribe
China 1126468 ➤ Subscribe
Cyprus 2389 ➤ Subscribe
Czech Republic 290266 ➤ Subscribe
Czech Republic 9600001 ➤ Subscribe
Germany 122010000043 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Novartis
UBS
US Army
QuintilesIMS
Harvard Business School
Accenture
Teva
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot